Compare CSGP & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSGP | AXSM |
|---|---|---|
| Founded | 1987 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4B | 12.0B |
| IPO Year | 1998 | 2015 |
| Metric | CSGP | AXSM |
|---|---|---|
| Price | $28.25 | $233.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 17 |
| Target Price | $60.57 | ★ $211.12 |
| AVG Volume (30 Days) | ★ 6.6M | 873.8K |
| Earning Date | 04-28-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.56 |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $965,230,000.00 | N/A |
| Revenue This Year | $19.71 | $57.24 |
| Revenue Next Year | $12.40 | $55.88 |
| P/E Ratio | $2,917.50 | ★ N/A |
| Revenue Growth | ★ 15.23 | N/A |
| 52 Week Low | $28.18 | $96.09 |
| 52 Week High | $97.43 | $260.19 |
| Indicator | CSGP | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 38.34 | 44.41 |
| Support Level | $28.18 | $217.15 |
| Resistance Level | $34.84 | $236.26 |
| Average True Range (ATR) | 1.27 | 9.92 |
| MACD | 0.05 | -1.50 |
| Stochastic Oscillator | 7.46 | 17.27 |
CoStar Group is a global provider of proprietary information, analytics, and online marketplaces serving both commercial and residential real estate. The firm operates through a diverse portfolio of brands, including CoStar Suite for commercial real estate research, LoopNet for commercial listings, Apartments.com for multifamily rentals, and Homes.com for residential brokerage. It primarily sells high-margin software-as-a-service subscriptions that provide institutional clients with forensic property data and premium advertising visibility. With operations across North America, Europe, and Asia-Pacific, CoStar maintains the industry's most comprehensive centralized real estate database, functioning as a critical information utility for brokers, lenders, and owners worldwide.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.